AARTIPHARM829.05

Aarti Pharmalabs Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersAARTIDRUGSADVENZYMESAGARWALEYEAKUMSALIVUSAPLLTDCORONAHCGMcap ₹7,516 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,852.62,115.11,819.41,969.0
Other Income4.910.19.78.2
Total Income1,857.52,125.21,829.21,977.2
Expenses
+ Cost of Materials Consumed858.4887.0830.1890.5
+ Purchases of Stock-in-Trade182.2176.655.961.5
+ Changes in Inventories-19.964.2-51.2-50.0
+ Employee Benefit Expense138.4162.0173.1182.2
+ Finance Costs17.226.946.953.0
+ Depreciation & Amortisation73.286.9104.3111.6
+ Other Expenses307.4360.9442.3458.6
Total Expenses1,557.01,764.51,601.51,707.3
EBITDA386.0464.4369.2426.3
EBIT312.8377.5264.9314.7
Profit
PBT before Exceptional Items300.5360.7227.7269.9
+ Exceptional Items0.00.0-2.8-2.8
Pretax Income300.5360.7224.9267.1
+ Current Tax55.867.542.249.7
+ Deferred Tax27.820.816.021.5
Tax Expense83.688.358.271.2
+ Share of Associates & JVs0.00.08.017.2
Net Income216.9272.4174.7213.1
+ Net Income — Continuing Ops216.9272.4166.7195.9
+ Other Comprehensive Income-0.5-9.8-6.2-5.6
Total Comprehensive Income216.4262.6168.5207.6
Net Income to Common216.4172.7212.2
Per Share
Basic EPS23.9330.0619.2723.51
Diluted EPS23.9330.0419.2523.50
Other Comprehensive Income — detail
+ Other Comprehensive Income-9.8-6.2-5.6
+ Tax on Items NOT to be Reclassified9.81.92.2
+ Tax on Items to be Reclassified0.04.33.3
+ Tax on Items to be Reclassified — alt tag0.5
Comprehensive Income — Owners of Parent216.4168.5179.6
Per Share — as-filed variants
Basic EPS — Continuing Operations23.9330.0619.2723.51
Diluted EPS — Continuing Operations23.9330.0419.2523.50
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit831.9987.2984.61,067.0
Gross Margin %44.9046.6754.1254.19
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)300.5360.7227.7269.9
− Exceptional Items (reconciliation)0.00.0-2.8-2.8
Net Income Adj (tax-effected)216.9272.4176.8215.2
EPS Adj23.9330.0619.5023.74
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value5.005.005.005.00
Paid Up Equity Capital45.345.345.345.3
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.